Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Liquidia Technologies Inc (LQDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/18/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "ELEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIQUIDIA TECHNOLOGIES, Inc.",
"SECOND AMENDED AND RESTATED BYLAWS OF LIQUIDIA TECHNOLOGIES, Inc.",
"Liquidia Closes Acquisition of RareGen"
11/16/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "Liquidia Announces Results of Special Meeting of Stockholders"
11/09/2020 8-K Quarterly results
Docs: "Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
11/02/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC"
10/19/2020 8-K Quarterly results
10/14/2020 8-K Quarterly results
08/20/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/24/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
06/05/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents"
05/18/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer RESEARCH TRIANGLE PARK, N.C., May 18, 2020 - Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced the appointment of Tushar Shah, M.D., to the newly created position of Chief Medical Officer. In this role, Dr. Shah will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia. Dr. Shah has 27 years of pharmaceutical research and development experience, successfully moving more than 20 products from discovery to commercialization. “Dr. Shah has had a long and distinguished career with nearly three decades of successful clinical d..."
05/11/2020 8-K Quarterly results
Docs: "Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update"
04/30/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension RESEARCH TRIANGLE PARK, N.C., April 30, 2020 - Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has released final safety and tolerability results from the two-month endpoint of the pivotal phase 3 INSPIRE trial that evaluated LIQ861 in patients with pulmonary arterial hypertension . Details from this late-breaking abstract were provided as an ePresentation on ISHLTv, an online platform designed as an alternative to the face-to-face scientific exchange originally scheduled at the International Society for H..."
04/13/2020 8-K Other Events
04/08/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension RESEARCH TRIANGLE PARK, N.C., April 08, 2020 - Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT technology, today announced that the U.S. Food and Drug Administration accepted for review the Company’ s New Drug Application seeking marketing approval for LIQ861 for the treatment of pulmonary arterial hypertension . Under the Prescription Drug User Fee Act , the FDA has set a goal date of November 24, 2020. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’ s novel PRINT tech..."
03/30/2020 8-K Other Events
03/20/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
01/27/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Submits New Drug Application for LIQ861 inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension RESEARCH TRIANGLE PARK, NC – Jan 27, 2020 – Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced the submission of its New Drug Application to the U.S. Food and Drug Administration for LIQ861. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using Liquidia’ s PRINT® technology with the goal of enhancing deep-lung delivery using a convenient, palm-sized dry powder inhaler for the treatment of pulmonary arterial hypertension . The NDA has been submitted under the 505 regulatory path..."
12/26/2019 8-K Quarterly results
12/04/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SEVERANCE AGREEMENT AND GENERAL RELEASE This SEVERANCE AGREEMENT AND GENERAL RELEASE is made and entered into by Liquidia Technologies, Inc. and Tim Albury . Throughout the remainder of the Agreement, the Company and Employee may be collectively referred to as the “Parties.” Employee has entered into an Amended and Restated Executive Employment Agreement with the Company dated July 25, 2018, and the First Amendment to the Amended and Restated Executive Employment Agreement dated March 8, 2019 . Employee’s employment by the Company will terminate pursuant to Section 6..."
11/18/2019 8-K Quarterly results
11/13/2019 8-K Quarterly results
11/01/2019 8-K Quarterly results
10/02/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
06/28/2019 8-K Quarterly results
06/05/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019 RESEARCH TRIANGLE PARK, NC — June 5, 2019 — Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial hypertension . As previously announced, the initial analysis of the INSPIRE study indicated the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint. Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 correlates with the 54 mcg dose of Tyvaso® , the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavai..."
05/24/2019 8-K Quarterly results
05/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, by and between Liquidia Technologies, Inc. and Dr. Richard Katz",
"Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy